Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2022-12-05 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin Launches Rufinamide Tablets USP in the United States.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Rufinamide Tablets USP) by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations, specifically Regulation 30, which relates to material events or information. The document does not contain financial statements, detailed financial analysis, or management discussion. It is a corporate announcement about a product launch, not a financial report, earnings release, or regulatory filing of financial data. The document length is 3741 characters, which is relatively short and typical for a press release. Therefore, it fits best under the category of a Regulatory Filing (RNS) as a general regulatory announcement and disclosure that does not fit into more specific categories like earnings release or annual report.
2022-12-05 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product (Rufinamide Tablets USP) by Lupin Limited. It is addressed to stock exchanges and references a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which pertains to material events or information. The document does not contain financial statements, detailed financial analysis, or regulatory certifications. It is a corporate announcement about a product launch, not a financial report, earnings release, or management discussion. The document length is 3733 characters, which is relatively short and consistent with a press release or regulatory announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit into more specific categories like earnings release or annual report.
2022-12-05 English
Intimation about loss of share certificate by shareholder.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements), 2015. It provides details of share certificates received from an investor requesting stop transfer. The content is a regulatory intimation related to share certificate handling and transfer restrictions, not a financial report, earnings release, or management discussion. The document length is short (2369 characters) and it is an official regulatory communication. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-11-29 English
Loss of share certificate
Regulatory Filings Classification · 100% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements), 2015, which pertains to details of share certificates and stop transfer requests. It is addressed to stock exchanges and signed by the company secretary. The content is a regulatory compliance communication about share certificate details, not a financial report, earnings release, or management discussion. It is a formal regulatory filing to comply with stock exchange rules, without financial data or report publication. Therefore, it fits best under Regulatory Filings (RNS). The document length is short and it is a certificate, not a report or announcement of a report.
2022-11-29 English
Lupin Launches Formoterol Fumarate Inhalation Solution in the United States.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations, specifically Regulation 30, which relates to material events or information. The document does not contain financial statements, detailed financial analysis, or management discussion. It is a corporate announcement about a product launch, not a financial report or regulatory filing of financial results. The document length is 3888 characters, which is relatively short and consistent with a press release or announcement. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2022-11-29 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to material events or information. The content is a corporate announcement about a product launch, not a financial report, earnings release, or regulatory filing. The document length is 3876 characters, which is relatively short and typical for a press release. There is no financial data, no management discussion, no voting results, no audit information, or other report content. Therefore, the document fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure that does not fit other specific categories.
2022-11-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.